Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Online CME Activity

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma Inc., Foundation Medicine Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Reata Pharmaceuticals.

Community Practice Connections: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

Release Date: April 28, 2017
Expiration Date: April 28, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® features a case-based discussion of current and developing therapies for patients with melanoma and Merkel cell carcinoma, including targeted therapy and immune checkpoint inhibitors. Interactive clinical vignettes are followed by short video interviews with leading experts in cutaneous malignancies and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with cutaneous malignancies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma Inc., Foundation Medicine Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Reata Pharmaceuticals.

CME/CE Activity Table of Contents

  • Module 1. Metastatic Melanoma (BRAF-Mutation Positive)
  • Module 2. Metastatic Melanoma (BRAF-wild type)
  • Module 3. Advanced Merkel Cell Carcinoma

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Choose treatment based on patient characteristics, such as age and performance status.
  • Assess the roles of regional therapies, targeted therapies, and immunotherapies in the treatment of patients.
  • Review strategies for mitigating and managing adverse events related to therapy.
  • Describe current and emerging strategies for individualizing therapy.
  • Evaluate emerging clinical data regarding new regional therapies, targeted therapies, and immunotherapies in treating melanoma and other cutaneous malignancies.

Faculty, Staff, and Planners' Disclosures

Faculty

Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Disclosure: Grant Support Research: Bristol-Myers Squibb (BMS), GlaxoSmithKline plc (GSK), Merck, Incyte, Genentech all to Moffitt; Consultant: BMS, GSK, Merck, Incyte, Genentech, AstraZeneca, Medivation; Shareholder: Altor, Celldex Therapeutics, cCAM Medical Ltd., CytomX Therapeutics; Other: named on a patent held by Moffitt that relates to a predictive marker for ipilimumab.

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosure: Grant Support Research: AstraZeneca, Bristol-Myers Squibb (BMS), Celldex Therapeutics, Genentech, Immunocore, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Rinat, Roche; Consultant: Amgen, Novartis, Roche, BMS, Merck; Shareholder: BMS, Genentech, Novartis, Amgen

Michael Postow, MD
Assistant Attending Physician
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Grant Support Research: Bristol-Myers Squibb (BMS); Consultant: BMS, Amgen, Novartis

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

 

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)
Management of BRAF-Mutant Melanoma

Featuring key melanoma experts Michael Postow, MD, and Jeffrey Weber, MD, PhD, this first of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes expert perspectives on a clinical vignette of a patient with metastatic melanoma and a BRAF-V600E mutation:

  • The clinical vignette involves a patient with symptomatic, BRAF-V600E mutation-positive melanoma. Although immunotherapy can be a frontline therapeutic option, expert recommendation for initial therapy is to pursue combination BRAF/MEK inhibition for rapid antitumor activity and symptom palliation.
  • Two combinations of a BRAF inhibitor and a MEK inhibitor are available: dabrafenib/trametinib and vemurafenib/cobimetinib. Both combinations have shown improved progression-free survival (PFS) and overall survival compared with single-agent BRAF inhibition. A third combination, encorafenib/binimetinib, has also demonstrated a PFS benefit over a BRAF inhibitor alone.
  • Combinations of immunotherapy with BRAF/MEK inhibitors are being studied. For example, phase I data have shown an overall response rate of 83% with the combination of atezolizumab with vemurafenib/cobimetinib in patients with BRAF-mutant melanoma, and the triplet is currently in phase III investigation.

 

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.




PER Pulse™ Recap (2 of 3)
Management of BRAF Wild-Type Melanoma

Featuring key melanoma experts Omid Hamid, MD, and Michael Postow, MD, this second of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes expert perspectives on a clinical vignette of a patient with metastatic melanoma and wild-type BRAF genes:

  • The clinical vignette involved a patient with metastatic BRAF wild-type melanoma. The expert recommendation is immunotherapy since BRAF inhibition is not indicated in patients with wild-type BRAF genes. For immunotherapy, inhibition of the PD-1/PD-L1 axis is preferable, as this approach has demonstrated superiority to single-agent CTLA-4 inhibition.
  • Currently, there are 2 anti–PD-1 antibodies available as single agents: pembrolizumab and nivolumab. In the KEYNOTE-006 trial, pembrolizumab demonstrated superior overall survival (OS) and progression-free survival (PFS) compared with ipilimumab, while nivolumab yielded superior OS and PFS compared with dacarbazine in the CheckMate 066 trial.
  • Initial results of the first-line CheckMate 067 trial showed that PFS was superior with nivolumab/ipilimumab or single-agent nivolumab compared with ipilimumab; updated results also demonstrated superior OS with both nivolumab-containing regimens.
  • Investigational approaches in patients with advanced BRAF wild-type melanoma include the addition of indoleamine 2, 3-dioxygenase inhibitors or MEK inhibitors to immune checkpoint inhibitors. Both approaches are in phase III investigation.

 

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.




PER Pulse™ Recap (3 of 3)
Advances in Merkel Cell Carcinoma

Featuring key experts in cutaneous malignancies Jeffrey Weber, MD, PhD, and Omid Hamid, MD, this third of 3 PER Pulse™ Recaps from Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® summarizes the development of immunotherapy in patients with Merkel cell carcinoma (MCC):

  • In March 2017, the anti–PD-L1 antibody avelumab received accelerated approval from the FDA based on phase II data from the JAVELIN Merkel 200 trial. This approval applies to patients ≥12 years of age with metastatic MCC. In the JAVELIN trial, avelumab yielded responses in 32% of patients, including complete responses (CRs) in 9% of patients.
  • Pembrolizumab has also demonstrated activity in MCC. In a phase II trial enrolling patients with no prior systemic therapy, pembrolizumab yielded an overall response rate of 56%, including CRs in 16% of patients,. Patients had a median progression-free survival of 9 months.

 

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By